In order to provide complete functionality, this web site needs your explicit consent to store browser cookies. If you don't allow cookies, you may not be able to use certain features of the web site including but not limited to: log in, buy products, see personalized content, switch between site cultures. It is recommended that you allow all cookies.

National Prescribing Indicators

National Prescribing Indicators
 
The All Wales Medicines Strategy Group (AWMSG) has endorsed the National Prescribing Indicators (NPIs) as a means of promoting safe and cost-effective prescribing.  NPIs have been published since 2003 and have historically focused on primary care prescribing.  In 2015 a set of secondary care NPIs were developed by the All Wales Prescribing Advisory Group (AWPAG) and launched by AWMSG for use in 2016–2017.  For 2016-17, there are 13 primary care NPIs focusing on seven areas of prescribing and the reporting of adverse events (Yellow Cards). Two of the indicators, lipid-regulating drugs and gabapentin and pregabalin, are new for 2016–20
 
The National Prescribing Indicators 2016–2017: Analysis of Prescribing Data to March 2017 document has been prepared by the Welsh Analytical Prescribing Support Unit and can be accessed on the link below:
 
http://www.awmsg.org/docs/awmsg/medman/National%20Prescribing%20Indicators%202016-2017%20Analysis%20of%20Prescribing%20Data%20to%20March%202017.pdf